Genomic diversity of prostate cancer across the african diaspora

Active Project Grant Awarded Last action

Award ID
R01CA259200
Recipient
Awarding agency
Obligated
$13,430,438

Award facts

Assistance listing
93.393 Cancer Cause and Prevention Research
Completion date 90% complete
Originally
Place of performance
Boston, MA 02215, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
African descent men (ADM) across the african diaspora have the highest rates of prostate cancer (cap) of any racial or ethnic group. The incidence rate in african american men (AAM) is 71% higher than in european american men (EAM) and the AAM mortality rate is 210% higher than EAM. Despite the public health implications of these observations, the underlying causes of this disparity remain unresolved. There is substantial evidence that social inequities and access to health care are in part responsible for cap disparities. There is limited consistent evidence for exposures and environmental factors in cap etiology or progression. In contrast, cap is strongly influenced by inherited genetic variation, and there is growing evidence that the mutational landscape of prostate tumors varies substantially by race. These observations suggest that biological factors influence cap incidence and tumor aggressiveness differentially by race and may in part explain cap disparities by race. To inform the biological basis of cap disparities that adversely affect ADM, we have developed a large, multicenter consortium known as "men of african descent and carcinoma of the prostate" (madcap). Using the resources of this consortium, we propose to undertake a study of cap in ADM to address the following aims: aim 1: identify common genetic variants associated with cap aggressiveness in ADM; aim 2: define histopathological commonalities of prostate tumors in ADM; and aim 3: evaluate molecular signatures and subtypes in prostate tumors and determine their relationship to pathological and clinical characteristics in ADM. The proposed research will have innovative impact in a number of ways. We will address the critical need for increased ethnic diversity in cancer genomics data, which to date has been dominated by studies in european ancestral populations. Ethnically diverse genetic data will not only improve our understanding of genomic contributors to cancer etiology and disparities but will also aid in the development and implementation of cancer genomic analysis for all populations, reduce the potential for errors in determining pathogenicity of genetic susceptibility variants, and improve interpretation of cancer risk in all populations including AAM. In undertaking this research, we will enhance infrastructure needed to undertake genomics research in africa that includes a large, well-annotated sample of systematically collected tumors with clinical and epidemiologic data that can be used to address a variety of research and clinical questions. We have constructed the madcap resources to integrate directly with existing publicly available databases, such as tcga/icgc and genie, to ensure the african data can be readily compared with data from other sources. Our data will also include deep pathology, clinical and risk factor annotation, largely unavailable in current public datasets, to provide a fuller potential to understand underlying disparities in cap etiology.

Transactions

Action Obligated Date
Amendment $44,377
Amendment $39,355
Amendment $56,012
Amendment $55,368
Amendment $48,417
Amendment Genetic and genomic variation in prostate cancer - there is consistent evidence that germline genetics and tumor (somatic) genomics have a substantial impact on… $53,769
Amendment Genomic and genomic variation in prostate cancer - there is consistent evidence that germline genetics and tumor (somatic) genomics have a substantial impact on… $19,607
Amendment Genetic and genomic variation in prostate cancer - there is consistent evidence that germline genetics and tumor (somatic) genomics have a substantial impact on… $19,607
Amendment $961,324
Amendment Genomic and genomic variation in prostate cancer - there is consistent evidence that germline genetics and tumor (somatic) genomics have a substantial impact on… $961,324
Amendment Genetic and genomic variation in prostate cancer - there is consistent evidence that germline genetics and tumor (somatic) genomics have a substantial impact on… $961,324
Amendment $53,769
Amendment $56,012
Amendment $44,377
Amendment $55,368
Amendment $48,417
Amendment $39,354
Amendment $19,607
Amendment $981,414
Amendment Genomic and genomic variation in prostate cancer - there is consistent evidence that germline genetics and tumor (somatic) genomics have a substantial impact on… $0
Amendment $66,147
Amendment $1,190,653
Amendment $1,190,653
Amendment $1,284,929
Amendment $1,284,929
Amendment $1,284,929
Amendment $1,284,929
Original award $1,324,467
Show all 28

Subawards

Subrecipient Amount Awarded
Stellenbosch University This proposal aims to conduct a genome-wide association study of prostate cancer in several African populations, with the eventual goal of identifying genetic… $56,012
Weill Medical College Of Cornell University The Biospecimen and Biomarker Core (BBC) provides key functions for biosample collection, processing, evaluation, storage, and biomarker generation to all three… $111,972
Wits Health Consortium (Pty) LTD This proposal aims to identify novel and validate known prostate cancer (CaP) loci in men of African descent to provide new information about the genetic… $53,769
Cancer Science Centre Abuja The goal of this supplement is to extend the capacity building opportunities in the Men of African Descent and Carcinoma of the Prostate (MADCaP) Network.… $44,377
College Of Medicine, University Of Ibadan The University College Hospital (UCH) in Ibadan, Nigeria, will be one of the recruitment sites in Africa for prostate cancer cases and controls for the proposed… $48,417
Institut Pour La Formation Et La Recherche En Urologie Et SA This proposal will identify biomarkers that may be useful in distinguishing aggressive from non-aggressive carcinoma of the prostate (CaP) in African men.… $55,368
37 Military Hospital The proposed study goals are to conduct a genome-wide association study (GWAS) of prostate cancer in Africans. Because epidemiologic studies in Africans are… $19,607
H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. Dr. Yamoah will be responsible for the overall direction and administration of Aim 2 at Moffitt and completion of reports and work with co-Pis and Co-ls on… $194,484
Georgia TECH Research Corp The goal of this supplement is to extend the capacity building opportunities in the Men of African Descent and Carcinoma of the Prostate (MADCaP) Network.… $73,152
Institut Pour La Formation Et La Recherche En Urologie Et SA This proposal will identify biomarkers that may be useful in distinguishing aggressive from non-aggressive carcinoma of the prostate (CaP) in African men.… $51,103
H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. Dr. Yamoah will be responsible for the overall direction and administration of Aim 2 at Moffitt and completion of reports and work with co-Pis and Co-ls on… $193,936
Wits Health Consortium (Pty) LTD This proposal aims to identify novel and validate known prostate cancer (CaP) loci in men of African descent to provide new information about the genetic… $49,627
37 Military Hospital The proposed study goals are to conduct a genome-wide association study (GWAS) of prostate cancer in Africans. Because epidemiologic studies in Africans are… $18,097
Georgia TECH Research Corp As a subcontractor for the proposed R01 to study the genetics and tumor biology of prostate cancer in men of African descent ( Genomic Diversity of Prostate… $67,555
Cancer Science Centre Abuja The goal of this supplement is to extend the capacity building opportunities in the Men of African Descent and Carcinoma of the Prostate (MADCaP) Network.… $85,645
Weill Medical College Of Cornell University The Biospecimen and Biomarker Core (BBC) provides key functions for biosample collection, processing, evaluation, storage, and biomarker generation to all three… $92,274
College Of Health Sciences, University Of Ghana The proposed study goals are to conduct a genome-wide association study of prostate cancer in Africans. Because epidemiologic studies in Africans are sparse,… $36,323
College Of Medicine, University Of Ibadan The University College Hospital (UCH) in Ibadan, Nigeria, will be one of the recruitment sites in Africa for prostate cancer cases and controls for the proposed… $47,448
H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. Dr. Yamoah will be responsible for the overall direction and administration of Aim 2 at Moffitt and completion of reports and work with co-Pis and Co-ls on… $186,870
Show all 19

Quick answers

Who received award R01CA259200?

R01CA259200 was awarded to Dana-Farber Cancer Institute, Inc. by National Cancer Institute (National Institutes of Health) on January 7, 2022.

How much is award R01CA259200 worth?

$13,430,438 has been obligated on R01CA259200.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login